Market Research Logo

Asthma Drugs Market in the US 2015-2019

Asthma Drugs Market in the US 2015-2019

About asthma

Asthma is a disease that affects the lungs and is characterized by wheezing, coughing, breathlessness, and chest tightness. It is a chronic ailment of the respiratory tract, which is caused by the obstruction of the flow of air and bronchospasms, where the muscles around the respiratory tract swell up. The disease is believed to be caused by genetic as well as environmental factors. The American Academy of Allergy Asthma and Immunology classifies asthma under four categories: exercise-induced asthma, allergic asthma, occupational asthma, and childhood asthma. The Asthma and Allergy Foundation of America classifies asthma into two categories: allergic asthma and non-allergic asthma. It is an incurable disease but can be controlled with the help of diagnosis at the right time, followed by regular therapy.

Technavio's analysts forecast the asthma drugs market in the US to grow at a CAGR of 4.64% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the asthma drugs market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sale of various classes of drugs used to treat asthma, which include:

  • Bronchodilators
  • Leukotriene antagonists
  • Mast cell stabilizers
  • Immunosuppressants
  • Combination of LABA/ICS


  • Technavio's report, Asthma Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

    Key vendors
    • AstraZeneca
    • F. Hoffmann-La Roche
    • GlaxoSmithKline
    • Merck
    Other prominent vendors
    • Abbott Laboratories
    • Addex Therapeutics
    • Alkermes
    • AstraZeneca
    • Aurobindo Pharma
    • Avanir Pharmaceuticals
    • Cerecor
    • Chugai Pharmaceutical
    • Dart NeuroScience
    • Dr. Reddy's Laboratories
    • Edgemont Pharmaceuticals
    • E-Therapeutics
    • Euthymics
    • Evotec
    • F. Hoffmann-La Roche
    • Fabre Kramer
    • Gedeon Richter
    • H. Lundbeck
    • Intra-Cellular Therapies
    • Janssen Pharmaceuticals
    • Lupin
    • Luye Pharma
    • MSI Methylation Sciences
    • Naurex
    • Neuralstem
    • Novartis
    • Opko Health
    • Otsuka Pharmaceutical
    • Pierre Fabre
    • Shire
    • SK Biopharmaceuticals
    • Somerset Pharmaceuticals
    • Sun Pharmaceutical
    • Sunovion Pharmaceuticals
    • Suven
    • Takeda Pharmaceutical
    • Teva Pharmaceutical
    • Torrent Pharmaceuticals
    • Valeant Pharmaceuticals
    Market driver
    • Rise in disease prevalence
    • For a full, detailed list, view our report
    Market challenge
    • Unknown disease etiology
    • For a full, detailed list, view our report
    Market trend
    • Popularity of combination therapies
    • For a full, detailed list, view our report
    Key questions answered in this report
    • What will the market size be in 2019 and what will the growth rate be?
    • What are the key market trends?
    • What is driving this market?
    • What are the challenges to market growth?
    • Who are the key vendors in this market space?
    • What are the market opportunities and threats faced by the key vendors?
    • What are the strengths and weaknesses of the key vendors?




    Press Release

    Technavio Announces the Publication of its Research Report – Asthma Drugs Market in the US 2015-2019

    Technavio recognizes the following companies as the key players in the asthma drugs market in the US: AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline and Merck

    Other Prominent Vendors in the market are: Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals and Valeant Pharmaceuticals

    Commenting on the report, an analyst from Technavio’s team said: “Patients with persistent asthma symptoms are treated with drugs for both symptomatic relief and as a preventive measure. This helps in the reduction of asthma flare-ups. Generally, a patient is prescribed LABA or leukotriene receptor antagonist (LTRA) along with ICS. LABA and LTRA differ in their mechanisms of action but both provide complementary benefits in combination with an ICS. They help to manage asthma by improving lung function, reducing symptoms, providing bronchoprotection, and controlling the underlying inflammation.”

    According to the report, pharmaceutical companies are developing drugs that have a better safety and efficacy profile than those already available in the market. These drugs are undergoing clinical trials or are awaiting approval by regulatory agencies. For instance, NVA237 by Novartis and Mepolizumab by GlaxoSmithKline are among the most promising drugs for the treatment of asthma. Mepolizumab by GlaxoSmithKline was submitted for approval as a maintenance treatment for severe eosinophilic asthma to the US Food and Drug Administration (FDA) in November 2014. Tralokinumab by AstraZeneca is another promising molecule, which is under phase III clinical trials.

    Further, the report states that the unknown etiology of the condition makes it difficult for pharmaceutical companies to develop a curative drug for the treatment of asthma.

    Companies Mentioned

    AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, Merck, Abbott Laboratories, Addex Therapeutics, Alkermes, AstraZeneca, Aurobindo Pharma, Avanir Pharmaceuticals, Cerecor, Chugai Pharmaceutical, Dart NeuroScience, Dr. Reddy's Laboratories, Edgemont Pharmaceuticals, E-Therapeutics, Euthymics, Evotec, F. Hoffmann-La Roche, Fabre Kramer, Gedeon Richter, H. Lundbeck, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Luye Pharma, MSI Methylation Sciences, Naurex, Neuralstem, Novartis, Opko Health, Otsuka Pharmaceutical, Pierre Fabre, Shire, SK Biopharmaceuticals, Somerset Pharmaceuticals, Sun Pharmaceutical, Sunovion Pharmaceuticals, Suven, Takeda Pharmaceutical, Teva Pharmaceutical, Torrent Pharmaceuticals, Valeant Pharmaceuticals

    • Executive Summary
    • List of Abbreviations
    • Scope of the Report
      • Market overview
      • Product offerings
    • Product Profiles
      • Accolate
        • Pulmicort
        • Symbicort
        • Xolair
        • Advair
        • Anoro Ellipta
        • Arnuity Ellipta
        • Breo Ellipta
        • Flovent
        • Serevent
        • Ventolin
        • Asmanex
        • Foradil
        • Dulera
        • Singulair
    • Market Research Methodology
      • Market research process
      • Research methodology
        • Table Market research methodology
    • Introduction
    • Disease Overview
      • Understanding the disease
      • Symptoms
      • Pathophysiology
        • Airway inflammation
        • Airway remodeling
      • Epidemiology
      • Diagnosis
        • Table Major diagnostic procedures for asthma
      • Management
    • Pipeline Portfolio
    • Market Landscape
      • Market overview
      • Market size and forecast
        • Table Asthma drugs market in US 2014-2019 ($ millions)
      • Five forces analysis
    • Market Segmentation by Class of Drug
      • Table Segmentation of asthma drugs market in US by class of drug
      • Table Segmentation of asthma drugs market in US by class of drug 2014
      • Table Segmentation of asthma drugs market in US by class of drug 2019
    • Bronchodilators
      • Bronchodilators market in US
        • Market overview
        • Market size and forecast
          • Table Bronchodilators market in US 2014-2019 ($ millions)
    • Combination of LABA/ICS
      • Combination of LABA/ICS market in US
        • Market overview
        • Market size and forecast
          • Table Combination of LABA/ICS market in US 2014-2019 ($ millions)
    • Immunosuppressants
      • Immunosuppressants market in US
        • Market overview
        • Market size and forecast
          • Table Immunosuppressants market in US 2014-2019 ($ millions)
    • Leukotriene Antagonists
      • Leukotriene antagonists market in US
        • Market overview
        • Market size and forecast
          • Table Leukotriene antagonists market in US 2014-2019 ($ millions)
    • Mast Cell Stabilizers
      • Mast cell stabilizers market in US
        • Market overview
        • Market size and forecast
          • Table Mast cell stabilizers market in US 2014-2019 ($ millions)
    • Buying Criteria
    • Market Growth Drivers
      • Table Major drivers of asthma drugs market in US
    • Drivers and their Impact
    • Market Challenges
      • Table Major challenges in asthma drugs market in US
    • Impact of Drivers and Challenges
    • Market Trends
      • Table Major trends in asthma drugs market in US
      • Table Prescription chart of popular asthma drugs in US 2013
    • Trends and Their Impact
    • Vendor Landscape
      • Competitive scenario
        • Key news
        • Mergers and acquisitions
      • Market share analysis 2014
        • Table Market share analysis 2014
        • Table YoY growth rate of major asthma drugs 2011-2014 ($ millions)
        • GlaxoSmithKline
          • Table GlaxoSmithKline: Global and US revenue of Breo Ellipta 2013 and 2014 ($ millions)
          • Table GlaxoSmithKline: Global revenue and YoY growth rate of Ventolin 2011-2014 ($ millions)
          • Table GlaxoSmithKline: US revenue and YoY growth rate of Ventolin 2011-2014 ($ millions)
          • Table GlaxoSmithKline: Global revenue and YoY growth rate of Flovent 2011-2014 ($ millions)
          • Table GlaxoSmithKline: US revenue and YoY growth rate of Flovent 2011-2014 ($ millions)
          • Table GlaxoSmithKline: Global revenue and YoY growth rate of Advair 2011-2014 ($ millions)
          • Table GlaxoSmithKline: US revenue and YoY growth rate of Advair 2011-2014 ($ millions)
          • Table GlaxoSmithKline: Global revenue and YoY growth rate of Serevent 2011-2014 ($ millions)
          • Table GlaxoSmithKline: US revenue and YoY growth rate of Serevent 2011-2014 ($ millions)
          • Table GlaxoSmithKline: US revenue of key asthma drugs 2011-2014 ($ millions)
        • AstraZeneca
          • Table AstraZeneca: Global revenue and YoY growth rate of Pulmicort 2011-2014 ($ millions)
          • Table AstraZeneca: US revenue and YoY growth rate of Pulmicort 2011-2014 ($ millions)
          • Table AstraZeneca: Global revenue and YoY growth rate of Symbicort 2011-2014 ($ millions)
          • Table AstraZeneca: US revenue and YoY growth rate of Symbicort 2011-2014 ($ millions)
          • Table AstraZeneca: US revenue of key asthma drugs 2011-2014 ($ millions)
        • F. Hoffmann-La Roche
          • Table F. Hoffmann-La Roche: Global revenue and YoY growth rate of Xolair 2011-2014 ($ millions)
        • Merck
          • Table Merck: Global revenue and YoY growth rate of Asmanex 2011-2013 ($ millions)
          • Table Merck: Global revenue and YoY growth rate of Dulera 2011-2014 ($ millions)
          • Table Merck: Global revenue and YoY growth rate of Singulair 2011-2014 ($ millions)
      • Other and future prominent vendors
    • Key Vendor Analysis
      • AstraZeneca
        • Key facts
        • Business overview
        • Business segmentation by revenue 2013
          • Table AstraZeneca: Business segmentation by revenue 2013
        • Business segmentation by revenue 2011-2013
          • Table AstraZeneca: Business segmentation by revenue 2011-2013 ($ millions)
        • Sales by geography
          • Table AstraZeneca: Sales by geography 2013
        • Business strategy
        • Key developments
        • SWOT analysis
      • F. Hoffmann-La Roche
        • Key facts
        • Business overview
        • Business segmentation
          • Table Business segmentation of F. Hoffmann-La Roche 2013
        • Business segmentation by revenue 2012 and 2013
          • Table F. Hoffmann-La Roche: Business segmentation by revenue 2012 and 2013
        • Sales by geography
          • Table F. Hoffmann-La Roche: Sales by geography 2013 (pharmaceuticals division)
          • Table F. Hoffmann-La Roche: Sales by geography 2013 (diagnostics division)
        • Business strategy
        • Key information
        • SWOT analysis
      • GlaxoSmithKline
        • Key facts
        • Business overview
        • Business segmentation by revenue 2014
          • Table GlaxoSmithKline: Business segmentation by revenue 2014
        • Business segmentation by revenue 2013 and 2014
          • Table GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
        • Geographical segmentation by revenue 2014
          • Table GlaxoSmithKline: Geographical segmentation by revenue 2014
        • Business strategy
        • Recent developments
        • SWOT analysis
      • Merck
        • Key facts
        • Business overview
        • Business segmentation by revenue 2013
          • Table Merck: Business segmentation by revenue 2013
        • Business segmentation by revenue 2012 and 2013
          • Table Merck: Business segmentation by revenue 2012 and 2013 ($ billions)
        • Sales by geography
          • Table Merck: Sales by geography 2013
        • Business strategy
        • Key developments
        • SWOT analysis
    • Other Reports in this Series

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report